WORLD CB AND CDX BOSTON 2019 (CLINICAL BIOMARKER AND COMPANION DIAGNOSTICS)September 9-12, 2019 The Renaissance Boston Waterfront, Boston, MA Flagship Biosciences is a proud Spotlight Partner of World CB and CDx Boston 2019. Flagship’s leaders will be speaking and...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Broomfield, CO – June 1, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company has moved its headquarters to a new location in Broomfield, Colorado, just north of Denver. The office, at 11800 Ridge...
Cambridge, MA and Westminster, CO — May 12, 2021 — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today...
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist InterpretationCambridge, MA and Westminster, CO – April 12, 2021 — Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a...
PUBLICATIONS/POSTERS
Key Takeaways Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
Key takeaways Building Predictive Models of Clinical Outcomes in Immune Oncology Using Computational Tissue Analysis Scorecards The spatial location of PD-L1 expression can identify patients who will likely respond to anti-PD-1/PD-L1 therapy Flagship’s unique spatial...
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of complex scoring schemes beyond the capacity of a human pathologist. However, this technology...